Diagnostic and prognostic role of 99mTc-Tetrofosmin in breast cancer

L. Mansi, P. F. Rambaldi, V. Cuccurullo, B. Pecori, M. Quarantelli, F. Fallanca, E. Del Vecchio

Research output: Contribution to journalArticle

Abstract

99mTc-Tetrofosmin (TF) is a lipophilic diphosphine compound routinely used for myocardial scintigraphy. Extracardiac utilization has occurred in evaluation of patients with malignant neoplasms and in parathyroid adenomas. Although its uptake mechanisms are not completely understood, they appear similar to those of 99mTc Sstamibi (MIBI). The importance of flow and the metabolic status of cells with an intracellular uptake depending on mitochondria and the Na+/K+ pump have been hypothesized. It has also been demonstrated that Tetrofosmin shares with MIBI the property of being a substrate for P-glycoprotein (P-gp), a multidrug resistance transporter. In this review the possible clinical role in breast cancer is analysed. First experiences suggest that scintimammography with TF is useful in patients with indeterminate Mammography and to obtain Complementary data to avoid surgery and/or biopsy. TF is a reliable tracer for diagnosis of primary cancer, of local recurrence, of axillary lymph node metastases. Preliminary data stimulate a possible role in functional imaging of chemoresistance and in differential diagnosis of distant metastases with main reference to the evaluation of single hot lesions at bone scan.

Original languageEnglish
Pages (from-to)239-250
Number of pages12
JournalQuarterly Journal of Nuclear Medicine
Volume41
Issue number3
Publication statusPublished - 1997

    Fingerprint

Keywords

  • Breast neoplasms diagnosis
  • Breast neoplasms radionuclide imaging
  • Organotechnetium compounds diagnostic use

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Mansi, L., Rambaldi, P. F., Cuccurullo, V., Pecori, B., Quarantelli, M., Fallanca, F., & Del Vecchio, E. (1997). Diagnostic and prognostic role of 99mTc-Tetrofosmin in breast cancer. Quarterly Journal of Nuclear Medicine, 41(3), 239-250.